{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:09:43Z","timestamp":1791461383080,"version":"4.3.4"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0234739","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T17:53:28Z","timestamp":1592502808000},"page":"e0234739","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study"],"prefix":"10.1371","volume":"15","author":[{"given":"Ian","family":"Pearce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-1557","authenticated-orcid":true,"given":"Andreas","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Brent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gallego-Pinazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Maria","family":"Minnella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-4598","authenticated-orcid":true,"given":"Catherine","family":"Creuzot-Garcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Spital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Dunger-Baldauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian L.","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of all the LUMINOUS\u2122 study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"issue":"2","key":"pone.0234739.ref001","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"S Rogers","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"pone.0234739.ref002","doi-asserted-by":"crossref","first-page":"010427","DOI":"10.7189\/jogh.09.010427","article-title":"Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors","volume":"9","author":"P Song","year":"2019","journal-title":"J Glob Health"},{"issue":"1","key":"pone.0234739.ref003","doi-asserted-by":"crossref","first-page":"P182","DOI":"10.1016\/j.ophtha.2015.10.045","article-title":"Retinal Vein Occlusions Preferred Practice Pattern((R)) Guidelines","volume":"123","author":"JS Pulido","year":"2016","journal-title":"Ophthalmology"},{"issue":"8","key":"pone.0234739.ref004","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"DM Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"pone.0234739.ref005","unstructured":"European Medicines Agency. Lucentis\u00ae Summary of Product Characteristics. Novartis Pharma AG, Basel, Switzerland. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000715\/WC500043546.pdf (Accessed on December 20, 2019). [Internet]."},{"key":"pone.0234739.ref006","unstructured":"Food and Drug Administration. Lucentis\u00ae Prescribing information. Genentech, Inc., San Francisco, California, USA. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125156s111lbl.pdf (Accessed on December 20, 2019). [Internet]."},{"issue":"4","key":"pone.0234739.ref007","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial","volume":"119","author":"JS Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"pone.0234739.ref008","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study","volume":"121","author":"PA Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"pone.0234739.ref009","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.ophtha.2014.06.011","article-title":"Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study","volume":"121","author":"PA Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"pone.0234739.ref010","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","article-title":"Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study","volume":"124","author":"R Tadayoni","year":"2017","journal-title":"Ophthalmology"},{"issue":"1","key":"pone.0234739.ref011","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1111\/aos.13381","article-title":"Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)","volume":"96","author":"LO Hattenbach","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"pone.0234739.ref012","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/1120672117750058","article-title":"A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion","volume":"28","author":"F Bandello","year":"2018","journal-title":"Eur J Ophthalmol"},{"key":"pone.0234739.ref013","unstructured":"Novartis data on file DSUR. 2018;(Nov)."},{"issue":"4","key":"pone.0234739.ref014","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"P Mitchell","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"pone.0234739.ref015","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/bjophthalmol-2015-307249","article-title":"Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study","volume":"100","author":"C Prunte","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"14","key":"pone.0234739.ref016","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"PJ Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0234739.ref017","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2016.02.030","article-title":"Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER","volume":"123","author":"R Tadayoni","year":"2016","journal-title":"Ophthalmology"},{"issue":"12","key":"pone.0234739.ref018","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","article-title":"Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study","volume":"100","author":"FG Holz","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"pone.0234739.ref019","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: Multicenter study of 92 976 ranibizumab injections: report 1: Visual acuity","volume":"121","author":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"pone.0234739.ref020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12886-017-0401-y","article-title":"Demographics of patients receiving intravitreal anti-VEGF treatment in real-world practice: Healthcare research data versus randomized controlled trials","volume":"17","author":"F Ziemssen","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"pone.0234739.ref021","article-title":"Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in Portugal","volume":"0","author":"S Vaz-Pereira","year":"2017","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"pone.0234739.ref022","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000488602","article-title":"Real-life clinical effectiveness of razumab(r) (the world's first biosimilar of ranibizumab) in retinal vein occlusion: A subgroup analysis of the pooled retrospective re-enact study","volume":"241","author":"Group R-ESI","year":"2019","journal-title":"Ophthalmologica"},{"key":"pone.0234739.ref023","unstructured":"Observe the effectiveness and safety of ranibizumab in real life setting (LUMINOUS) [cited 2019 December 20]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01318941."},{"issue":"4","key":"pone.0234739.ref024","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3346\/jkms.2015.30.4.475","article-title":"Baseline predictors of visual acuity and retinal thickness in patients with retinal vein occlusion","volume":"30","author":"SJ Kim","year":"2015","journal-title":"J Korean Med Sci"},{"key":"pone.0234739.ref025","article-title":"Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: Results from LUMINOUS, a global real-world study","author":"FG Holz","year":"2019","journal-title":"Retina"},{"key":"pone.0234739.ref026","article-title":"Effectiveness and safety of ranibizumab 0.5 mg in treatment-na\u00efve patients with diabetic macular edema: Results from the real-world global LUMINOUS study","author":"P Mitchell","year":"2019","journal-title":"Manuscript submitted to PLOS ONE"},{"issue":"8","key":"pone.0234739.ref027","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/aos.12772","article-title":"Anti-VEGF treatment in branch retinal vein occlusion: A real-world experience over 4 years","volume":"93","author":"S Rezar","year":"2015","journal-title":"Acta Ophthalmol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T17:54:06Z","timestamp":1592502846000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234739"}},"subtitle":[],"editor":[{"given":"Alfred S","family":"Lewin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0234739","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]}}}